Abbott Laboratories (ABT) 주식 개요
애보트 연구소는 자회사와 함께 전 세계에서 헬스케어 제품을 발견, 개발, 제조, 판매하고 있습니다. 자세히 보기
ABT Community Fair Values
Create NarrativeSee what 247 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Top Community Narratives
US$113.88
FV
21.4% 저평가 내재 할인율6.57%
Revenue growth p.a.
95
users have viewed this narrative1users have liked this narrative
0users have commented on this narrative
4users have followed this narrative
Abbott Laboratories 경쟁사
가격 이력 및 성과
| 과거 주가 | |
|---|---|
| 현재 주가 | US$89.46 |
| 52주 최고가 | US$139.06 |
| 52주 최저가 | US$89.14 |
| 베타 | 0.78 |
| 1개월 변동 | -12.62% |
| 3개월 변동 | -18.15% |
| 1년 변동 | -32.65% |
| 3년 변동 | -19.59% |
| 5년 변동 | -24.79% |
| IPO 이후 변동 | 24,328.54% |
최근 뉴스 및 업데이트
Abbott Laboratories: Buying A Healthcare Giant On Sale
Apr 24
ABT: AF Portfolio And Dividend Track Record Will Support Future Repricing
Analysts have trimmed Abbott Laboratories' implied fair value estimate to $118.64 from $131.44. This reflects a series of recent price target reductions as they factor in updated growth, margin and P/E assumptions.Recent updates
Abbott Laboratories: Buying A Healthcare Giant On Sale
Apr 24ABT: AF Portfolio And Dividend Track Record Will Support Future Repricing
Analysts have trimmed Abbott Laboratories' implied fair value estimate to $118.64 from $131.44. This reflects a series of recent price target reductions as they factor in updated growth, margin and P/E assumptions.ABT: AF Portfolio And Dividend Track Record Will Support Future Upside
Abbott Laboratories' updated analyst price target reflects a modest reset, with fair value moving from $132.64 to $131.44 as analysts factor in higher assumed revenue growth of 10.24%, a lower profit margin of 15.60% and a slightly richer future P/E of 30.91x. Analyst Commentary Recent research on Abbott Laboratories points to an active debate around how much investors should pay for the stock, with several price target changes clustered over the past few months.ABT: AF Portfolio Advancements And Dividend Streak Will Support Future Upside
Analysts have trimmed Abbott Laboratories' fair value estimate by about $0.70 to $132.64. This reflects a series of recent target cuts across the Street, even as they continue to reference generally healthy medtech sector fundamentals.ABT: AF Portfolio Progress And Dividend Streak Will Drive Future Upside
Analysts have trimmed their average price targets on Abbott Laboratories by a few dollars, reflecting slightly higher required returns and refreshed assumptions on fair value, while still grounding their views in recent research that includes both target cuts and at least one upward revision. Analyst Commentary Recent research on Abbott Laboratories gives you a mixed but useful read on how the Street is thinking about valuation, execution, and growth.ABT: Exact Sciences Deal And AF Portfolio Will Reshape Future Upside
Analyst targets on Abbott Laboratories have moved lower by double digit dollar amounts, with multiple firms trimming their price objectives in U.S. dollars as they factor in updated assumptions on discount rates, long term revenue growth, margins and future P/E expectations. Analyst Commentary Recent Street research on Abbott Laboratories reflects a mix of caution on valuation and optimism around the company’s longer term positioning, with several firms resetting price targets and one firm upgrading the stock.ABT: Exact Sciences Deal Will Reshape Testing Franchise And Future Upside
Analysts have trimmed their fair value estimate for Abbott Laboratories by about $3 to roughly $133. This reflects modestly softer revenue growth assumptions, a slightly lower future P/E multiple near 30x, and recent reductions in price targets across several firms, even as some still highlight the pending Exact Sciences deal as a key part of their thesis.ABT: Exact Sciences Acquisition Will Shape Future Earnings Mix And Upside Potential
Analysts have reduced their fair value estimate for Abbott Laboratories by about $8 to $136.47, reflecting a series of recent price target cuts that incorporate slightly adjusted growth, discount rate and P/E assumptions, along with expectations for a modestly higher profit margin profile. Analyst Commentary Recent research updates show a mix of optimism and caution around Abbott Laboratories, with several firms adjusting price targets and factoring in the pending Exact Sciences acquisition.ABT: Exact Sciences Deal And Legal Wins Will Support Future Upside
Narrative Update Overview The updated analyst work on Abbott Laboratories reflects a small increase in the implied fair value to about $144.75. Analysts point to a tighter discount rate, steady growth and margin assumptions, and a blended view of recent price target changes that factor in medical devices momentum, the pending Exact Sciences deal, and reduced legal overhangs.Returns On Capital Are Showing Encouraging Signs At Abbott Laboratories (NYSE:ABT)
Jan 03
ABT: Exact Sciences Deal And Legal Wins Will Drive Future Returns
Analysts modestly raised their average price target for Abbott Laboratories to about $144 per share, citing resilient mid-single digit organic revenue growth, double digit earnings power supported by a diversified healthcare portfolio, accelerating momentum in Medical Devices despite some near term lumpiness, and potential strategic upside from the pending Exact Sciences acquisition at a premium takeout valuation. Analyst Commentary Street research remains broadly constructive on Abbott, with recent notes highlighting both upside drivers and areas of near term scrutiny as investors digest the Exact Sciences transaction and mixed quarterly optics.ABT: Exact Sciences Deal And Legal Wins Will Drive Future Upside
Analysts made a modest adjustment to their Abbott Laboratories price targets, with estimates moving in a roughly $2 range around the mid-$140s as they balanced optimism around the pending Exact Sciences acquisition, resilient device driven growth, and favorable legal developments against some near term lumpiness in non device segments. Analyst Commentary Research coverage around Abbott remains largely constructive, with most views anchored on a durable devices growth profile, incremental benefits from the proposed Exact Sciences transaction, and diminishing legal overhangs.ABT: Exact Sciences Acquisition And Legal Wins Will Drive Medium-Term Upside
Abbott Laboratories’ analyst price target saw a modest decrease to $144.43 as analysts point to shifting expectations around profit margin and a slightly higher discount rate. This development is tempered by optimism for ongoing revenue growth and stability in core medical device performance.ABT: Momentum From Legal Win And Product Approvals Will Support Future Gains
Analysts have modestly revised their price targets for Abbott Laboratories, with recent updates ranging from $142 to $146 per share. They cite strong momentum in Medical Devices and a resilient, diversified business model, despite varied performance across business segments.Abbott Laboratories' (NYSE:ABT) Earnings Are Weaker Than They Seem
Nov 05ABT: Legal Wins And Device Momentum Will Support Durable Growth Ahead
Abbott Laboratories' average analyst price target experienced a modest increase to approximately $144.47. Analysts cited positive legal developments and continued momentum in the Medical Devices segment as key factors supporting the adjustment.Expanding Emerging Markets And Diagnostics Will Drive Prospects Despite Headwinds
Analysts have modestly increased their price target for Abbott Laboratories from $142.48 to $144.40, citing resilient growth in medical devices and expectations for steady double-digit earnings growth, even though there may be some near-term variability across business segments. Analyst Commentary Recent research notes reflect a mix of optimism and caution from analysts following Abbott Laboratories' latest results and updates to price targets.There's No Escaping Abbott Laboratories' (NYSE:ABT) Muted Earnings
Sep 15Abbott Q1: Flexible Supply Chain And Strong Growth In Medical Devices
Apr 16Abbott Laboratories Basking In A Sharp Turn In Sentiment
Mar 16Abbott Laboratories: Now Back In The Buy Zone (Rating Upgrade)
Jan 23Abbott Laboratories Q4 2024 Earnings Preview
Jan 08주주 수익률
| ABT | US Medical Equipment | US 시장 | |
|---|---|---|---|
| 7D | -1.8% | -4.3% | 0.8% |
| 1Y | -32.6% | -18.7% | 27.7% |
수익률 대 산업: ABT은 지난 1년 동안 -18.7%의 수익을 기록한 US Medical Equipment 산업보다 저조한 성과를 냈습니다.
수익률 대 시장: ABT은 지난 1년 동안 27.7%를 기록한 US 시장보다 저조한 성과를 냈습니다.
주가 변동성
| ABT volatility | |
|---|---|
| ABT Average Weekly Movement | 3.3% |
| Medical Equipment Industry Average Movement | 8.2% |
| Market Average Movement | 7.2% |
| 10% most volatile stocks in US Market | 16.2% |
| 10% least volatile stocks in US Market | 3.3% |
안정적인 주가: ABT는 지난 3개월 동안 US 시장에 비해 주가 변동성이 크지 않았습니다.
시간에 따른 변동성: ABT의 주간 변동성(3%)은 지난 1년 동안 안정적이었습니다.
회사 소개
| 설립 | 직원 수 | CEO | 웹사이트 |
|---|---|---|---|
| 1888 | 115,000 | Robert Ford | www.abbott.com |
애보트 연구소는 자회사와 함께 전 세계에서 헬스케어 제품을 발견, 개발, 제조 및 판매합니다. 네 가지 부문으로 운영됩니다: 기존 제약 제품, 진단 제품, 영양 제품, 의료 기기입니다. 이 회사는 췌장 외분비 기능 부전, 과민성 대장 증후군 또는 담도 경련, 간내 담즙 정체 또는 우울 증상, 부인과 장애, 호르몬 대체 요법, 이상 지질 혈증 치료를 위한 일반 의약품을 제공합니다, 고혈압, 갑상선 기능 저하증, 고중성지방혈증, 메니에르병 및 전정 현기증, 통증, 발열, 염증, 편두통, 항감염성 클라리트로마이신, 인플루엔자 백신, 대장 생리적 리듬 조절 제품 등을 제공합니다.
Abbott Laboratories 기초 지표 요약
| ABT 기초 통계 | |
|---|---|
| 시가총액 | US$158.14b |
| 순이익 (TTM) | US$6.25b |
| 매출 (TTM) | US$45.13b |
24.9x
주가수익비율(P/E)3.5x
주가매출비율(P/S)ABT는 고평가되어 있습니까?
공정 가치 및 평가 분석 보기순이익 및 매출
| ABT 손익계산서 (TTM) | |
|---|---|
| 매출 | US$45.13b |
| 매출원가 | US$19.63b |
| 총이익 | US$25.50b |
| 기타 비용 | US$19.25b |
| 순이익 | US$6.25b |
최근 보고된 실적
Mar 31, 2026
다음 실적 발표일
해당 없음
| 주당순이익(EPS) | 3.59 |
| 총이익률 | 56.50% |
| 순이익률 | 13.85% |
| 부채/자본 비율 | 64.8% |
ABT의 장기 실적은 어땠습니까?
과거 실적 및 비교 보기| Abbott Laboratories 배당 일정 | |
|---|---|
| 배당락일 | Apr 15 2026 |
| 배당 지급일 | May 15 2026 |
| 배당락일까지 남은 일수 | 17 days |
| 배당 지급일까지 남은 일수 | 13 days |
ABT는 안정적으로 배당을 지급합니까?
ABT 배당 기록 및 벤치마크 보기기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/05/01 11:33 |
| 종가 | 2026/05/01 00:00 |
| 수익 | 2026/03/31 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Abbott Laboratories는 52명의 분석가가 다루고 있습니다. 이 중 24명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| David Toung | Argus Research Company |
| Adam Feinstein | Barclays |
| Matthew Miksic | Barclays |